Schulz Marten, Choi Mira, Bachmann Friederike, Koch Nadine, Holtmann Theresa Maria, Mohr Raphael, Tacke Frank, Wree Alexander
Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Quant Imaging Med Surg. 2022 Jul;12(7):3528-3538. doi: 10.21037/qims-21-1178.
Hepatitis E virus (HEV) infection especially in immunocompromised individuals can lead to chronic hepatitis. Aggressive courses of chronic hepatitis E leading to liver cirrhosis in a short period of time have been described, but evidence on the degree of liver involvement in chronic hepatitis E is rare. We therefore aimed to quantify liver fibrosis in patients with chronic active hepatitis E compared to patients with sustained virological response after ribavirin (RBV) treatment using 2D-shear wave elastography (2D-SWE) to measure liver stiffness.
Patients with chronic hepatitis E underwent 2D-SWE, B-mode and Doppler ultrasound and laboratory testing in order to assess severity of liver involvement.
In this cross-sectional study, we included 14 patients of whom 8 had ongoing chronic hepatitis E and 6 patients had been successfully treated for chronic hepatitis E. The most frequent cause for immunosuppression was prior kidney transplantation (n=12), one patient was a multivisceral transplant recipient, one had been treated for lymphoma. Five patients cleared HEV after RBV therapy, one patient reached viral clearance after reduction of his immunosuppressive medication. Using 2D-SWE measurement, 71.4% displayed increased stiffness indicative of liver fibrosis: 57.1% classified as significant fibrosis and 14.3% as severe fibrosis. Liver stiffness did not differ between patients with active chronic hepatitis E and in patients who had cleared HEV (1.59 and 1.54 m/s respectively). Compared with a control group of kidney transplant recipients without hepatitis E (1.44 m/s), the patients with a history of hepatitis E displayed a significantly higher liver stiffness (P=0.04).
In our cohort of chronic hepatitis E patients, elevated liver stiffness indicating liver fibrosis was common and significantly higher than in controls. This is consistent with prior sparse reports of the presence of liver fibrosis or cirrhosis in chronic hepatitis E and emphasizes the need for HEV testing, therapy and research on new therapeutic options. As elevated liver stiffness was also present in patients after HEV treatment, continuous liver surveillance including elastography and ultrasound should be considered.
戊型肝炎病毒(HEV)感染,尤其是在免疫功能低下的个体中,可导致慢性肝炎。已有报道称,慢性戊型肝炎的侵袭性病程可在短时间内导致肝硬化,但关于慢性戊型肝炎肝脏受累程度的证据却很少。因此,我们旨在使用二维剪切波弹性成像(2D-SWE)测量肝脏硬度,以量化慢性活动性戊型肝炎患者与利巴韦林(RBV)治疗后获得持续病毒学应答的患者的肝纤维化情况。
慢性戊型肝炎患者接受二维剪切波弹性成像、B超和多普勒超声检查以及实验室检测,以评估肝脏受累的严重程度。
在这项横断面研究中,我们纳入了14例患者,其中8例患有持续性慢性戊型肝炎,6例慢性戊型肝炎患者已成功接受治疗。免疫抑制最常见的原因是既往肾移植(n=12),1例患者为多脏器移植受者,1例曾接受淋巴瘤治疗。5例患者在接受RBV治疗后清除了HEV,1例患者在减少免疫抑制药物用量后实现了病毒清除。通过二维剪切波弹性成像测量,71.4%的患者表现出硬度增加,提示肝纤维化:57.1%被归类为显著纤维化,14.3%为严重纤维化。活动性慢性戊型肝炎患者和已清除HEV的患者之间的肝脏硬度无差异(分别为1.59和1.54米/秒)。与无戊型肝炎的肾移植受者对照组(1.44米/秒)相比,有戊型肝炎病史的患者肝脏硬度显著更高(P=0.04)。
在我们的慢性戊型肝炎患者队列中,提示肝纤维化的肝脏硬度升高很常见,且显著高于对照组。这与先前关于慢性戊型肝炎存在肝纤维化或肝硬化的稀疏报道一致,并强调了进行HEV检测、治疗以及研究新治疗方案的必要性。由于HEV治疗后的患者也存在肝脏硬度升高的情况,应考虑进行包括弹性成像和超声检查在内的持续肝脏监测。